Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SPD's Beck wants measured approach to stem cell law review

This article was originally published in Clinica

Executive Summary

The head of German's SPD party, Kurt Beck, has rejected calls by the German research society (DFG) for a rapid liberalisation of the law on stem cell research. "This would be the wrong way to go," he said in an interview published by Rheinisch Merkur, indicating that the associated ethical issues warrant a considered approach to any review of the law. He advocated a bolder policy for the use of stem cell therapies in the most seriously ill, however. But his fundamental views have set him on a collision course with Chancellor Angela Merkel, who has expressly asked the scientific community to offer ideas that can serve as the basis for an overhaul of Germany's stem cell legislation.

You may also be interested in...

Big Win For EMA On Transparency

The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.

UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector

Dr Reddy’s Focuses On India And China

Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts